Table 1.
Demographic and clinical characteristics of patients with confirmed COVID‐19 who had hidradenitis suppurativa (HS)
| Total (n = 39) | Not hospitalized (n = 31) | Hospitalized (n = 8) | P‐valuesa | |
| Demographic data | ||||
| Age (years) | 42·1 ± 12·6 | 40·5 ± 10·9 | 48·0 ± 17·3 | 0·14 |
| Female sex | 31 (80) | 27 (87) | 4 (50) | 0·04 |
| Race/ethnicity | ||||
| Black/African American | 12 (31) | 10 (32) | 2 (25) | |
| Non‐Hispanic | 0·90 | |||
| Asian, non‐Hispanic | 1 (3) | 1 (3) | 0 | |
| White, non‐Hispanic | 16 (41) | 12 (39) | 4 (50) | |
| Hispanic | 10 (26) | 8 (26) | 2 (25) | |
| Clinical data | ||||
| BMI (kg m−2) | 34·4 ± 7·5 | 33·8 ± 7·2 | 36·9 ± 8·9 | 0·30 |
| Current or past smoking | 11 (28) | 8 (26) | 3 (38) | 0·66 |
| Diabetes | 12 (31) | 7 (23) | 5 (63) | 0·08 |
| Hypertension | 14 (36) | 10 (32) | 4 (50) | 0·42 |
| Asthma | 11 (28) | 8 (26) | 3 (38) | 0·66 |
| Cardiovascular disease | 5 (13) | 3 (10) | 2 (25) | 0·27 |
| Renal disease | 1 (3) | 0 | 1 (13) | 0·21 |
| Anxiety/depression | 14 (36) | 11 (36) | 3 (38) | 1·00 |
| Pregnant | 2 (5) | 2 (7) | 0 | 1·00 |
| Current HS therapy | ||||
| Biologic | 1 (3) | 1 (3) | 0 | 1·00 |
| Systemic antibiotic | 7 (18) | 4 (13) | 3 (38) | 0·14 |
| Topical therapy | 7 (18) | 6 (19) | 1 (13) | 1·00 |
| COVID outcomes | ||||
| Supplemental oxygen | 4 (10) | |||
| ICU admission | 3 (8) | |||
| Orotracheal intubation | 3 (8) | |||
| Death | 1 (3) | |||
BMI, body mass index; ICU, intensive care unit. aComparison between patients on any systemic therapy and nonsystemic therapy, using two‐sided Student’s t‐test or Fisher’s exact test for continuous and categorical variables, respectively. Data are presented as mean ± SD or n (%).